Latent tuberculosis screening among new users of a biologic or targeted synthetic DMARD: gaps in screening overall and among Janus kinase inhibitors.
Eric T RobertsGabriela SchmajukJing LiMatthew MurrillRebecca GraingerPublished in: Arthritis care & research (2024)
We report higher screening rates than have previously been published due to combining claims and EHR data. However, important safety gaps remain, namely, reduced screening among new users of a JAKi or IL-17i, among Asian and Hispanic patients, and low performing practices. Educational initiatives, team-based care delivery, task shifting and technological interventions to address observed gaps in patient safety procedures are needed.
Keyphrases
- patient safety
- quality improvement
- healthcare
- palliative care
- end stage renal disease
- rheumatoid arthritis
- electronic health record
- primary care
- newly diagnosed
- ejection fraction
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- big data
- systematic review
- machine learning
- african american
- human immunodeficiency virus
- adverse drug
- hepatitis c virus